Aignostics

Aignostics is a company specializing in computational pathology, developing AI models for pharmaceutical research and diagnostics. The platform enables the precise analysis of tissue sections to identify biological markers and support clinical decision-making. By combining high-resolution image processing with machine learning, complex pathological patterns are made quantifiable.

The technological core is based on a validated environment specifically tailored to the requirements of clinical trials and drug development. The system processes histological sections to map the interaction between tumor tissue and the immune system in detail. The provider places great emphasis on reproducibility and compliance with regulatory standards for medical software.

Companies primarily use this solution to increase success rates in drug development through more precise patient selection. The platform offers seamless integration into existing laboratory workflows and supports experts in evaluating large datasets. Automating repetitive analysis tasks saves time and increases the objectivity of diagnostic findings.

• AI-powered Histopathology — Automated identification and segmentation of tissue structures and cells in histological samples. This enables objective and standardized quantification of biomarkers.
• Validated Analysis Pipeline — Development and deployment of algorithms complying with strict regulatory requirements for the pharmaceutical industry. The focus is on high precision and clinical validity of results.
• Bioinformatics Integration — Merging image data with molecular biological data to generate comprehensive insights into disease progression. The platform supports a holistic view of the biological tissue being examined.

The tool is primarily aimed at pharmaceutical companies, biotech organizations, and academic research institutions. It is particularly relevant for pathologists, oncologists, and data scientists in the field of translational medicine.

A pharmaceutical company uses Aignostics during a Phase II clinical trial to predict the response rate to a new immunotherapy drug. Histological sections from patient biopsies are uploaded to the platform to precisely measure the spatial density of tumor-infiltrating lymphocytes. The AI automatically segments the tissue and classifies the immune 'hot' or 'cold' properties of the tumor. Based on these objective quantifications, the research team can better stratify the patient cohort. This leads to more efficient study evaluation and more informed decisions regarding the drug development process.

• The tool is primarily aimed at pharmaceutical companies, biotech organizations, and academic research institutions. It is particularly relevant for pathologists, oncologists, and data scientists in the field of translational medicine.
• A pharmaceutical company uses Aignostics during a Phase II clinical trial to predict the response rate to a new immunotherapy drug.
• AI-powered Histopathology: Automated identification and segmentation of tissue structures and cells in histological samples. This enables objective and standardized quantification of biomarkers.
• Validated Analysis Pipeline: Development and deployment of algorithms complying with strict regulatory requirements for the pharmaceutical industry. The focus is on high precision and clinical validity of results.
• Bioinformatics Integration: Merging image data with molecular biological data to generate comprehensive insights into disease progression. The platform supports a holistic view of the biological tissue being examined.

Aignostics is not designed for general image management without analysis requirements or for private, non-clinical use. Furthermore, it should not be applied without the necessary expertise for interpreting pathological AI results in a clinical environment.

• contextflow — Paid · HQ: Wien, Austria · GDPR / EU
• deepc — Paid · HQ: München, Germany · GDPR / EU
• mediaire — Paid · HQ: Berlin, Germany · Unclear
• Vara — Paid · HQ: Berlin, Germany · GDPR / EU